MicroRNA-372 acts as a double-edged sword in human cancers

MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3′-UTR mRNAs and controlling gene expression at the post-transcriptional level...

Full description

Saved in:
Bibliographic Details
Published inHeliyon Vol. 9; no. 5; p. e15991
Main Authors Tajik, Fatemeh, Alian, Fatemeh, Yousefi, Mohammad, Azadfallah, Ali, Hoseini, Aref, Mohammadi, Forogh, Karimi-Dehkordi, Maryam, Alizadeh-Fanalou, Shahin
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2023
Elsevier
Subjects
Cancer
carcinogenesis
Function
gene expression
humans
Importance
microRNA
MicroRNA-372
neoplasm progression
neoplasms
Oncogene
oncogenes
pathophysiology
Review
therapeutics
Tumor suppressor
Importance
Function
MicroRNA-372
Tumor suppressor
Oncogene
Cancer
Online AccessGet full text

Cover

More Information
Summary:MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3′-UTR mRNAs and controlling gene expression at the post-transcriptional level. As an oncogene, miRNAs can either accelerate cancer progression or slow it down as a tumor suppressor. MicroRNA-372 (miR-372) has been found to have an abnormal expression in numerous human malignancies, implying that the miRNA plays a role in carcinogenesis. It is both increased and downregulated in various cancers, and it serves as both a tumor suppressor and an oncogene. This study examines the functions of miR-372 as well as the LncRNA/CircRNA-miRNA-mRNA signaling pathways in various malignancies and analyses its potential prognostic, diagnostic, and therapeutic implications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Fatemeh Tajik and Fatemeh Alian equally contributed to the manuscript.
ISSN:2405-8440
2405-8440
DOI:10.1016/j.heliyon.2023.e15991